LCN2 and cholangiocarcinoma: The All-7 panel consisted of all candidate CCA biomarkers (S100A9, AACT, AFM, TAOK3, NGAL, PSMA3, and AMBP) identified by the plasma proteomic analysis of the nine pooled samples and from the literature (Figure 2 and Table 2).